NASDAQ: BMRN

Company Deals Drug

Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand

Fineline Cube Feb 24, 2025

Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...

Company

BioMarin to Cut 225 Jobs Amid Challenges in Gene Therapy Commercialization

Fineline Cube Aug 30, 2024

US-based BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is navigating a challenging period marked by difficulties in...

Company

BioMarin Pharmaceutical to Discontinue Vimizim Import License in China

Fineline Cube Jun 8, 2023

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its decision not to renew the Import Drug...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Company Drug

AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer